STOCK TITAN

uniQure N.V. - QURE STOCK NEWS

Welcome to our dedicated news page for uniQure N.V. (Ticker: QURE), a resource for investors and traders seeking the latest updates and insights on uniQure N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect uniQure N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of uniQure N.V.'s position in the market.

Rhea-AI Summary
uniQure receives FDA clearance for gene therapy candidate AMT-260 for refractory MTLE; clinical trial initiation expected in Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.86%
Tags
-
Rhea-AI Summary
uniQure N.V. reported encouraging interim analysis data from a Phase I/II clinical trial of AMT-130 in Huntington's disease, showing preservation of function and clinical benefits. They also announced plans for clinical trials in refractory temporal lobe epilepsy and SOD1-ALS, and the submission of an IND for Fabry disease. The company has a strong cash position of $628.6 million and sold a royalty interest in HEMGENIX® for up to $400 million. They appointed a new Chief Medical Officer and Chief Legal Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.23%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
uniQure N.V.

Nasdaq:QURE

QURE Rankings

QURE Stock Data

228.67M
37.70M
9.88%
81.66%
5.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Netherlands
Amsterdam

About QURE

uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.